natgillin/translations-raw huggingface dataset:
The present invention relates to a pharmaceutical composition comprising levetiracetam as active ingredient and 2.0 to 9.0% per weight of disintegrant, 0.0 to 3.0% per weight of gliding agent, 0.5 to 6.0% per weight of binder, and 0.0 to 1.0% per weight of lubricant, with respect to the total weight of the pharmaceutical composition, and to a process for its preparation. CROSS-REFERENCE TO RELATED APPLICATIONS This application is a U.S. National Stage of International Application No. 
Farmaceutski pripravak koji sadrži levetiracetam kao aktivni sastojak i 2.0 do 9.0% po težini dezintegriranog sredstva, naznačen time da je odabran iz skupine koju čine polivinilpolipirolidon, 1 natrijeva kroskarmeloza, 0.0 do 3.0% po težini klizno sredstvo, odabrano iz skupine koja se sastoji od talka, škroba, stearinske kiseline i anhidridnog koloidnog silikagela, 0.5 do 6.0% po težini vezivnog sredstva, odabranog iz skupine koja se sastoji od makrogola, mikrokristalne celuloze, saharoze, manitola i sorbitola, i 0.0 do 1.0% po težini sredstva za podmazivanje, odabranog iz skupine koja se sastoji od talka, magnezijevog stearata i kalcijevog stearata, u odnosu na ukupnu težinu farmaceutskog pripravka.
The method of claim 8, wherein the amount of the compound of formula R1SR2 ranges from about 1.0 to about 9.0, from about 2.0 to about 5.0 or from about 2.5 to about 3.5 molar equivalents per molar equivalent of trichloroisocyanuric acid. 
Postupak prema zahtjevu 1, naznačen time da je količina agensa za aciliranje u rasponu od oko 1 do oko 15, od oko 1 do oko 10 ili od oko 2 do oko 7 molarnih ekvivalenata po molarnom ekvivalentu spoja formule (II).
Ingredient in the present invention 
Sastojak u ovom izumu
determining the most unfavorable zone within the portion of water, wherein the most unfavorable zone presents the lowest ORP value within the portion of water intended for recreational purposes after dispensing chemical agent; 
određivanjem najnepovoljnije zone unutar dijela vode, gdje najnepovoljnija zona predstavlja najnižu vrijednost ORP unutar dijela vode namijenjenog za rekreaciju nakon upotrebe kemijskog sredstva;
A lower maximum level of the drug in the blood can reduce the severity of dose-dependent side effects and thus may improve drug tolerance. 
Niža maksimalna razina lijeka u krvi može smanjiti težinu dozno-ovisnih nuspojava, te stoga može poboljšati prihvaćanje lijeka.
Numerous variations and modifications of detail within the reach of a person skilled in the art can be made to the present invention without thereby departing from the scope of the invention as set forth in the appended claims. 
Ovom se izumu mogu pridodati brojne varijacije i modifikacije pojedinosti koje su sve u dometu tehnički iskusnih osoba u ovom području, a da se pri tome ne odstupi od samoga izuma izloženog u patentnim zahtjevima u privitku.
The compound of clause 1, wherein R1 is H. 
Spoj prema zahtjevu 1, pri čemu Ri je H, i/ili pri čemu R2» je H.
The rodent of claim 3, wherein said humanized SIRPa protein comprises amino acid residues 28-362 of SEQ ID NO: 4. 
Glodavac u skladu s patentnim zahtjevom 3, naznačen time što navedeni humanizirani protein SIRPa sadrži aminokiselinske ostatke 28-362 u SEQ ID NO: 4.
Inhibition of tankyrases of compounds of the formula I 
Datum objave europske prijave patenta:
In a further embodiment, the conditions suitable for forming the compound of formula (I) or hydrate thereof comprises combining a solution of the reagent comprising sodium ions in a polar solvent and water with the solution of the amine salt of the compound of formula (II) as obtained from the preceding step. 
O=P-OH | (ll) OH s aminom pod uvjetima koji su pogodni za nastajanje soli amina spoja s formulom (II); i b) dovođenje u kontakt soli amina s reagensom koji sadrži natrijeve ione pod uvjetima koji su pogodni za nastajanje spoja s formulom (1) ili njegovog hidrata.
For example, the silk fibroin gel forms less than four hours after ultrasonication treatment, such as within two hours after the ultrasonication treatment. 
Postupak prema zahtjevu 1, gdje do formiranja geliranog fibroina svile dolazi u manje od dva sata nakon obrade ultrazvukom.
Dexanabinol, or a salt thereof, for use in the treatment of melanoma. 
Deksanabinol, ili njegova sol, za upotrebu u liječenju melanoma.
A pharmaceutical composition according to claim 13 formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, and suspensions. 
Farmaceutski sastav prema zahtjevu 13, u obliku tableta, pilula, dražeja, kapsula, tekućina, gelova, sirupa, krema ili suspenzija.
contacting a positive terminal of the direct current power supply with the aqueous solution; 
stavljanje u doticaj pozitivnog priključka direktne energetske opskrbne mreže s vodenom otopinom;
correlating the presence or absence of the immunological complex with the presence or absence of amyloid protein in the specific body part or area; and comparing the amount of said immunological complex before and after onset of the treatment, wherein a decrease in the amount of said immunological complex indicates that said patient has a high potential of being responsive to the treatment. 
koreliranju prisutnosti ili odsutnosti imunološkog kompleksa s prisutnošću ili odsutnošću amiloidnog antigena u uzorku; i uspoređivanju količine navedenog imunološkog kompleksa prije i nakon početka liječenja, gdje smanjenje količine navedenog agregata ukazuje da navedeni pacijent ima visoki potencijal da reagira na liječenje.
An agomelatine hydrobromide hydrate of formula I according to claim 1 in the form of crystalline form, exhibiting the following crystal parameters: space group P21/c, lattice parameters a = 7.5943 (7), b = 23.4046 (19), c = 9.6438 (8) Å, B = 1613.9 (2)°. 
Agomelatin hidrobromid hidrat formule I u skladu s patentnim zahtjevom 1, u kristalnom obliku, naznačen time, da ima sljedeće kristalne parametre: prostorna grupa P21/c, parametri rešetke a = 7,5943 (7), b = 23,4046 (19), c = 9,6438 (8) Å, B = 1613,9 (2) °.
The lighting module of claim 1, wherein said microchip is configured to operate the switching device such that substantially 330 mA is delivered to the light emitting diode when said thermistor senses 100° C. 
Rasvjetni modul iz patentnog zahtjeva 1, naznačen time, da navedeni mikročip konfiguriran da upravlja preklopnim sklopom tako da se LED diodi isporučuje 330 mA kada navedeni termistor odčita temperaturu od 100
The process of item 15, wherein the temperature of step c) is the target temperature of the extended release matrix formulations and wherein the curing step starts when the temperature of the extended release matrix formulations reaches said temperature and the curing step ends either when the heating is stopped or at least reduced and the temperature of the extended release matrix formulations subsequently drops below said temperature by more than about 10 °C or below about 62 °C, in a plateau-like temperature profile or when the temperature of the extended release matrix formulations drops below said temperature in a parabolic or triangular temperature profile. 
. Postupak prema zahtjevu 15, naznačen time da je temperatura koraka c) ciljana temperatura formulacije matrice s produljenim otpuštanjem i gdje korak stvrdnjavanja započinje kada temperatura formulacije matrice s produljenim otpuštanjem dosegne navedenu temperaturu i korak stvrdnjavanja završava ili kada se zaustavi zagrijavanje ili kada je barem smanjeno te izlazna temperatura zraka naknadno pada ispod navedene temperature za više od oko 10 *C ili ispod oko 62 *C, u temperaturnom profilu nalik platou ili kada temperatura formulacije matrice s produljenim otpuštanjem padne ispod navedene temperature u paraboličnom ili trokutastom temperaturnom profilu.
In an embodiment the composition comprises from 94-96 wt % of tetrafluorethane, from 2-3 wt % of difluoromethane and from 2-3 wt % of pentafluoroethane. 
Pripravak rashladnog plina naznačen time da sadrži smjesu od 94 do 96 tež.% 1,1,1,2-tetrafluoretana, od 2 do 3 tež.% difluormetana i od 2 do 3 tež.% pentafluoretana.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) mandipropamid. 
Spoj prema zahtjevu 1, naznačen time, da sadrži kao komponentu (A) spoj (9-difluorometiliden-benzonorbornen-5ilamid 3-difluorometil-1-metil-1H-pirazol-4-karboksilne kiseline, te kao komponentu (B) mandipropamid.
The formulation in the form of a hard or soft gelatin capsule, tablet, or coated tablet according to claim 18 wherein said composition consists of 5 to 17 parts by weight of beeswax, 5 to 30 parts by weight of honey, and 65 to 90 parts by weight of cocoa butter for a total of 100 parts by weight. 
Formulacija u obliku tvrde ili meke želatinske kapsule, tableta, obložene tablete u skladu s patentnim zahtjevom 18, naznačena time, da se navedeni pripravak sastoji od 2 do 17 težinskih udjela pčelinjeg voska, 5 do 30 težinskih udjela meda 1 65 do 90 težinskih udjela kakao maslaca od ukupno 100 težinskih udjela .
The use of claim 43, wherein the aerosol comprises greater than about 50 mg/ml levofloxacin and magnesium chloride, has a pH from about 5.5 to about 6.5, and an osmolality from about 350 mOsmol/kg to about 750 mOsmol/kg. 
Uporaba iz patentnog zahtjeva 43, pri čemu aerosol obuhvaća više od oko 50 mg/ml levofloksacina 1 magnezij klorida, ima pH od oko 5,5 do oko 6,5, i osmolarnost od oko 350 mOsmol/kg do oko 750 mOsmol/keg.
Examples of the abovementioned animal pests are: 
Datum objave europske prijave patenta:
removing at least 10% of said organic acid from said liquid while retaining at least 65% of said at least one micro-nutrient in said liquid, wherein said organic acid is removed through an Anion Exchange Reverse Electro-Enhanced Dialysis (AX-REED) membrane stack and wherein said process is continued until a predetermined pH is reached, simultaneously removing at least part of one organic acid and at least part of one cation from the liquid obtained in step d), while retaining at least 65% of said at least one micro-nutrient in said liquid, thereby obtaining a REED liquid wherein said organic acid is removed through an Anion Exchange Reverse Electro-Enhanced Dialysis (AX-REED) membrane stack; and said cation is removed through an Cation Exchange Reverse Electro-Enhanced Dialysis (CX-REED) membrane stack; and wherein said process is continued until a predetermined conductivity is reached, 
(li) s enzimom ili smjesom enzima koja može katalizirati pretvaranje glukoze da se dobije organska kiselina i/ili ili) s jednim ili više mikroorganizama koji fermentiraju šećer koji su sposobni fermentirati šećer u organsku kiselinu i/ili iv) s enzimom ili smjesom enzima koja može katalizirati pretvaranje šećera da se dobije organska kiselina; 1 d) uklanjanje najmanje 15 % organske kiseline nastale u koraku c) iz navedene tekućine uz zadržavanje najmanje 65 % navedene najmanje jedne mikro hranjive tvari u navedenoj tekućini, te se tako dobiva tekućina AX-REED, pri čemu se navedeni kiseli ion uklanja pomoću stoga membrana za anionsku izmjenu reverznom elektro poboljšanom dijalizom,Anion Exchange Reverse Electro-Enhanced Dialysis" (AX-REED), navedeni stog membrana sadrži i)
Fig. 2 shows a cross-sectional view of the sheath device connected to a scope, 
Slika 2 prikazuje izgled poprečnog presjeka uređaja za omatanje koji je spojen na endoskop,
A pharmaceutical dosage formulation suitable for oral administration comprising the compound having the structure: or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. 
Farmaceutska dozna formulacija pogodna za oralnu administraciju koja sadrži spoj koji ima strukturu: ili njegovu farmaceutski prihvatljivu sol i farmaceutski prihvatljiv nosač.
In another embodiment, the amino acid is at a concentration range of about 0.5 mM to about 300 mM. 
Formulacija prema zahtjevu 6, naznačena time da je amino kiselina u koncentraciji od oko 0.5 mM do oko 300 mM u otopini.
In other embodiments, the condition is an eye disorder, such as uveitis, macular degeneration, glaucoma, diabetic macular edema, blepharitis, diabetic retinopathy, a disease or disorder of the corneal endothelium, post-surgical inflammation, dry eye, allergic conjunctivitis or a form of conjunctivitis. In some embodiments, the eye disorder is macular degeneration. 
Spoj, polimorfni oblik ili farmaceutski pripravak za upotrebu prema zahtjevu 11, naznačen time da stanje je poremećaj oka odabran od uveitisa, makularne degeneracije, glaukoma, dijabetičkog makularnog edema, blefaritisa, dijabetičke retinopatije, bolesti ili poremećaja endotela rožnice, postoperativna upala, sindrom suhog oka, alergijski konjunktivitis, te oblik konjunktivitis.
Compounds according to claim 1, wherein the compounds of formula (I) are of formula (Ib): wherein: 
Spojevi prema zahtjevu 1, naznačeni time da spojevi s formulom (1) su sa formulom (Ib):
Such equivalents are intended to be encompassed by the following claims. A method for treating hair, wherein the hair comprises two or more free thiol groups, comprising: 
PATENTNI ZAHTJEVI m» Postupak za tretiranje kose, gdje kosa sadrži dvije ili više slobodnih tiolnih skupina, naznačen time da sadrži:
one to three additional therapeutic agents, optionally wherein the one to three one additional therapeutic agents is an anti-HIV agent, optionally wherein the one to three additional therapeutic agents is selected from the group consisting of HIV protease inhibitors, HIV non-nucleoside inhibitors of reverse transcriptase, HIV nucleoside or nucleotide inhibitors of reverse transcriptase, and combinations thereof; or ii) a first additional therapeutic agent selected from the group consisting of: abacavir sulfate, tenofovir, tenofovir disoproxil fumarate, tenofovir alafenamide, and tenofovir alafenamide hemifumarate and a second additional therapeutic agent selected from the group consisting of emtricitibine and lamivudine. 
jedan do tri dodatna terapeutska sredstva, proizvoljno pri čemu je jedno do tri dodatna terapeutska sredstva sredstvo protiv HIV-a, proizvoljno pri čemu je jedno do tri dodatna terapeutska sredstva izabrano iz skupine koju čine inhibitori HIV proteaze, HIV nenukleozidni inhibitori reverzne transkriptaze, HIV nukleozidni ili nukleotidni inhibitori reverzne transkriptaze, i njihove kombinacije; ili ii) prvo dodatno terapeutsko sredstvo izabrano iz skupine koju čine: abakavir sulfat, tenofovir, tenofovir dizoproksil fumarat, tenofovir alafenamid, i tenofovir alafenamid hemifumarat i drugo terapeutsko sredstvo izabrano iz skupine koju čine emtricitibin i lamivudin.
The compound of claim 5, wherein ring B is phenyl, pyridinyl, pyrimidinyl, or pyrazinyl; each of which may be optionally substituted, preferably wherein ring B is substituted by alkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, aralkyl, haloalkyl, hal, OH, NH2, NHR", CN, N3, or NO2. 
Spoj prema patentnom zahtjevu 5, naznačen time što prsten B je fenil, piridinil, pirimidinil ili pirazinil; od kojih svaki može biti izborno supstituiran, poželjno gdje je prsten B supstituiran sa alkil, aril, heteroaril, cikloalkil, heterocikloalkil, aralkil, haloalkil, hal, OH, NH,, NHR", CN, Nz ili NO».
Lock according to Claim 12, wherein the lower closing elements (8) are larger in size than the upper closing elements (7). 
Zatvarač (1) u skladu s patentnim zahtjevom 12, kod kojeg su donji elementi zatvaranja (8) veći od gornjih elemenata zatvaranja (7).
In the figures, the same reference signs are used for the same or similar components, wherein same or similar characteristics or advantages are achieved, even if a repeated discussion is omitted. 
Na slikama, za iste ili slične komponente koriste se isti odnosni znakovi, pri čemu se postižu iste ili slične karakteristike ili prednosti iako je izostavljeno ponavljanje rasprave.
The method of claim 17, wherein therapeutically effective amount of crenolanib or a salt thereof is administered orally, intravenously, or intraperitoneally. 
Pripravak namijenjen uporabi u skladu s patentnim zahtjevom 23, pri čemu se terapeutski djelotvorna količina crenolaniba ili njegove soli daje oralno, intravenozno ili intraperitonealno.
a pneumatic system, supplied by the source of compressed air, comprising valve means for commanding supply to the motor and for commanding the compression and discharge runs of the piston internally of the cylinder, respectively destined to raise the pressure of the oil-dynamic fluid up to a maximum predetermined value, and to reduce the pressure of the oil-dynamic fluid. 
pneumatički sustav, opremljen izvorom stlačenog zraka, koji ima ventilni element za upravljačko napajanje motora i za upravljanje tlačećim 1 popuštajućim hodom klipa unutar cilindra, radi povećavanja tlaka uljno-dinamičkog fluida do najveće zadane vrijednosti, odnosno smanjivanja tlaka uljno-dinamičkog fluida;
A system according to any one of claims 1 to 10, wherein said at least one first electromagnetic radiation (EMR) waveguide (130) comprises an optical interface adapted to couple electromagnetic radiation of said predetermined first wavelength into said reactor chamber (103). 
Sustav prema bilo kojem od Zahtjeva 1 do 10, gdje najmanje jedan prvi valovod (130) za elektromagnetno zračenje (EMR) sadrži optičko sučelje koje je prilagođeno da proslijedi elektromagnetno zračenje navedene unaprijed određene prve valne duljine u navedenu komoru (103) reaktora.
represents hydrogen or methyl; 
predstavlja vodik ili metil;
wherein R, R1, R2, R3, R4 and R5 are independently selected from the group consisting of —H and a C1-C10 alkyl or aralkyl group, and wherein Xaa1 is selected from the group consisting of charged amino acids, aromatic amino acids and hydrophobic amino acids and protease-resistant variants thereof selected from D-stereoisomer or cyclized residue, 
[image] [image] [image] naznačeno time što su R, R1, R2, R3, R4 i R5 nezavisno odabrani od -H, C1-C10 alkil ili aralkil grupe, pri čemu su poželjno R, R1, R2, R3, R4 i R5 nezavisno odabrani od H i CH3, i pri čemu je Xaa1 izabran iz grupe koja se sastoji od naelektriziranih aminokiselina, aromatičnih aminokiselina i hidrofobnih aminokiselina i njihovih varijanti otpornih na proteazu, ili njegova farmaceutski prihvatljiva sol.
The second emulsion may be formed by circulating the second emulsion components through a microfluidization device 4 to 7 times. 
Postupak patentnog zahtijeva 10, naznačen time da se druga emulzija formira cirkuliranjem komponenti druge emulzije kroz uređaj za mikrofluidizaciju tri puta.
4-chlorophenyl CH3 a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof, a tautomeric form thereof or a N -oxide form thereof. 
Spoj naznačen time da se bira od [image] [image] njegova farmaceutski prihvatljiva kisela ili bazna adicijska sol, njegov stereokemijski izomerni oblik, njegov tautomerni oblik ili njegov oblik N-oksida.
The compound according to Claim 4, wherein R3 represents phenyl, indolyl, or indazolyl, which may be substituted respectively with a group selected from Group Q, Group Q is a group consisting of halogen, lower alkyl, halogeno-lower alkyl, - OR0, lower alkylene-OR0, -S-lower alkyl, aryl, a heterocyclic group, and lower alkylene-heterocyclic group (wherein, the aryl and heterocyclic group in Group Q may be substituted with halogen, cyano, lower alkyl, -OR0, or oxo), and R0 represents -H or lower alkyl. 
predstavlja aril ili heteroaril, koji mogu redom biti supstituirani grupom odabranom iz grupe Q; grupa Q je grupa koja se sastoji od halogena, C1-6 alkila, halogeno-C1-6 alkila, -OR0, C1-6 alkilen-OR0, -S-C1-6alkila, arila, heterocikličke grupe, i C1-6 alkilen-heterocikličke grupe, gdje aril i heterociklička grupa u grupi Q mogu biti supstituirani halogenom, cijano, C1-6 alkilom, -OR0, ili okso: i
In accordance with this concept, if we consider the full protection of the animal as: EPMATHMARKEREP where A is the rate of animals with thrombotic occlusion in treated group; and B is the rate of animals with thrombotic occlusion in the control group. 
U skladu s ovim konceptom, ako punu zaštitu životinje smatramo kao: Frakcijska inhibicija = (1-A/B) x 100 gdje A je broj životinja s tromboznom okluzijom u liječenoj skupini; i B je broj životinja s tromboznom okluzijom u kontrolnoj skupini.
The process according to claim 1 wherein R′ is an aliphatic chain containing 1-8 carbon atoms. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što R' je alifatski lanac s 1-8 atoma ugljika.
Analgecine for use as a medicament according to claim 1, wherein analgecine improves H2O2-induced injury of PC12 cells or analgecine improves glutamic acid-induced injury of a PC12 cell or analgecine inhibits expression or excretion of ICAM-1 by an endothelial cell in a cerebral vessel or analgecine inhibits the transformation of T-and B-lymphocytes. 
Analgecine za uporabu kao lijek prema zahtjevu 1, gdje analgecine poboljšava H;O,-induciranu ozljedu PC12 stanica ili analgecine poboljšava ozljedu PC12 stanice induciranu glutaminskom kiselinom ili analgecine inhibira ekspresiju 1li izlučivanje ICAM-1 iz endotelnih stanica u žilama mozga ili analgecine inhibira transformaciju T- i B-limfocita.
The transmitter of claim 8, wherein the L1 block has L1 signaling information for the data slice. The transmitter of claim 8, further comprising: 
Uređaj prema zahtjevu 8 ili 9, naznačen time, što L1 blok ima LI signalizacijsku informaciju za signaliziranje podatkovnog odsječka.
Composition comprising influenza virosomes comprising reconstituted envelopes of influenza virus for use in inducing a systemic and/or local immune response against the influenza antigens haemagglutinin and/or neuraminidase or derivatives thereof in a human being by means of a single intranasal or inhalational administration, wherein 
PATENTNI ZAHTJEVI Pripravak koji sadrži virosome gripe koji sadrže rekonstituirane ovojnice virusa gripe za uporabu kod induciranja sistemskog i/ili lokalnog imunog odgovora protiv antigena gripe hemaglutinina i/ili neuraminidaze ili njihovih derivata kod čovjeka putem jednostrukog intranazalnog ili inhalacijskog davanje, naznačen time da
The device 1 also comprises means to rotate the guide 6 about a hinge axis 100 . 
Uređaj 1 također ima sredstvo za rotiranje vodilice 6 oko osi zgloba 100.
A method of treating myocardial infarction in a human comprising administering to such human N-[(1,3-dicyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine, or a pharmaceutically acceptable salt thereof. 
ili njihovih farmaceutski prihvatljivih soli ili solvata. N-[(1,3-Dicikloheksil-6-hidroksi-2,4-diokso-1,2,3,4-tetrahidro-5-pirimidinil)karbonil]glicin, naznačen time što ima formulu [image], ili njegova farmaceutski prihvatljiva sol.
• addition and agitation of flour and thickeners into the obtained mixture, 
dodavanje i miješanje brašna i zgušnjivača u nastalu smjesu, .
A drug substance comprising about 5% to about 100% by weight of the crystalline monohydrate of Claim 4. 
Supstanca lijeka, naznačena time, da sadržava oko 5% do oko 100% težinski kristalnog monohidrata iz Zahtjeva 4.
A method for manufacturing wood preservative composition, in which method, wood preservative composition is manufactured of crude tall oil by distilling from the unsaponifiable components of the crude tall oil the following components: (b1) resin alcohols, (b2) steroids and 
Postupak proizvodnje pripravka za konzerviranje drva, gdje se u navedenom postupku pripravak za konzerviranje drva proizvodi iz sirovog talovog ulja destiliranjem iz neosapunjivih komponenata sirovog talovog ulja sljedećih komponenata:
The composition as claimed in claim 2, wherein a weight fraction of all phospholipids, based on the total weight of the composition, is greater than 120.0 mg/l. 
Kompozicija za primjenu u postupku sukladno zahtjevu 2, naznačena time, što je težinski udio svih fosfolipida, bazirano na ukupnoj težini kompozicije, veći od 120,0 mg/l.